Industry Concerned Over EMA Plan To Make More PIP Information Public
Executive Summary
The European Medicines Agency’s plan to publish details of the studies and measures it agrees with a drug developer for a pediatric investigation plan will help other companies in framing their future marketing authorization applications. But there are concerns that the agency's plan might result in the disclosure of commercially confidential information.
You may also be interested in...
EMA's Proposal To Disclose Key Elements Of Pediatric Plans On Hold For Now
A year after the European Medicines Agency announced plans to publicly disclose the key elements of pediatric investigation plans to make its regulatory decisions more transparent, concerns around confidentiality issues and resources means no final decision has yet been made on the implementation of this controversial proposal.
Pharma Opposes 'Harmful' Changes To EMA’s Access To Documents Policy
The EU pharmaceutical industry has concerns about the European Medicines Agency’s proposal to grant extended access to documents on orphan designations and pediatric investigation plans under its revised access to documents policy. The changes would discourage innovation and lead to inadvertent disclosure of commercially sensitive data, companies claim.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.